January 2016, Vol. 3, No. 1
A New Year for ImmunotherapyLetter to Our Readers
I hope you had great holidays and a happy New Year! In this first issue of the year, we feature an in-depth review about immune checkpoint inhibition in patients with colorectal cancer. This is a continuation of our series on immunotherapy in specific disease states. In this article, we provide information on microsatellite instability and DNA mismatch, as well as data on combination therapy with the drugs pembrolizumab, nivolumab plus ipilimumab, and durvalumab.
“Because the prognosis for patients with recurrent or metastatic colorectal cancer is very poor, alternative strategies such as immunotherapy are needed to improve outcomes for patients with advanced disease,” the author concluded.
In addition, we highlight recent data on pembrolizumab combination therapy and data indicating antitumor activity.
You will read about the latest research in immunotherapy as part of the conference coverage of the 2015 Society for Immunotherapy of Cancer 30th Anniversary Annual Meeting. In particular, we discuss the clinical benefits associated with T-cells in patients with glioblastoma, the significance of mitochondrial activity in CD8T–natural killer cell interaction, and targeted therapy in patients with renal or ovarian cancers who express B7-H4 receptors.
In this issue, we also provide an interesting perspective on the impact of the Affordable Care Act. Let us know your thoughts about this article.
We hope you will enjoy this issue, and look forward to your continued feedback. This is a brand new year for immunotherapy. Look to Immunotherapy in Oncology for the latest data on advancements in molecular sequencing, targeted therapies, and new diagnostic modalities.
Sanjiv S. Agarwala, MD
Immunotherapy in Oncology
In 3 phase 1 and 2 studies, improved overall response rates (ORRs) were shown in patients with metastatic melanoma taking pembrolizumab (Keytruda) in combination with 3 other immunotherapies, including epacadostat, talimogene laherparepvec (Imlygic), and ipilimumab (Yervoy). All 3 studies demonstrated significant antitumor activity. In addition, long-term follow-up data in a [ Read More ]
According to the American Cancer Society, colorectal cancer is the third most common cancer in men and women, and the second leading cause of cancer deaths in the United States.1 An estimated 132,700 new cases of, and 49,700 deaths from, colorectal cancer are expected to occur in 2015. For patients [ Read More ]